press releases 2010  

• January 4, - Pieris Appoints a New CEO   
  
  

press releases 2009  

• October 9, - Pieris reports preclinical development progress of its next generation VEGF antagonist   
   
• September, 15 - Pieris AG enters into Anticalin Collaboration with Allergan, Inc.  
  
  
• February, 3 - Pieris reports development progress for Anticalin PRS-050, a next generation VEGF antagonist and expands its management team to support program success  
  
  

press releases 2008 

• July, 16 - Wacker validates scalability of Anticalin production with E.coli secretion technology and will produce Pieris first clinical candidate PRS-050 
  
  
• March, 27 - Pieris raises € 25 M (US$ 38 M) in Series B financing round led by OrbiMed Advisors LLC  
  
  

 press releases 2007 

• November, 8 - Pieris strengthens its management, as it prepares for the clinical development of PRS-050, an Anticalin-based novel cancer therapy 
  
  
• October, 30 - Pieris and Pepscan to identify GPCR-specific Anticalins using CLIPS™ protein mimicry technology     
  
  
• September, 5 - Pieris validates the use of Anticalins as ophthalmologic biotherapeutics 
  
  
• July, 10 - Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin-based protein product candidate   
  
  
• June, 21 - Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin technology    
  
  
• March, 29 - Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin in preclinical studies